https://www.selleckchem.com/pr....oducts/cobimetinib-g
RESULTS Of 187 897 eligible patients, 21 757 (11.6%) were NSAID users. 854 (0.45%) developed PCCRC-3y (proximal cancer 147 [17.2%]). NSAIDs were associated with a lower PCCRC-3y risk (aHR 0.54, 95% CI 0.41-0.7, but not CRC that developed 3 years (aHR 0.78, 95% CI 0.56-1.09). The aHR was 0.48 (95% CI 0.24-0.95) for proximal and 0.55 (95% CI 0.40-0.74) for distal cancer. A duration- and frequency response relationship was observed (Ptrend less then 0.001). For aspirin, the aHR was 1.01 (95% CI 0.80-1.28). CONCLUS
Respect!
Kommentar
Delen
